Stifel Financial Corp Has $6.71 Million Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Stifel Financial Corp boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 10.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,194 shares of the medical instruments supplier's stock after purchasing an additional 7,060 shares during the period. Stifel Financial Corp owned approximately 0.32% of LeMaitre Vascular worth $6,706,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. boosted its stake in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock valued at $40,000 after buying an additional 183 shares during the last quarter. USA Financial Formulas bought a new position in shares of LeMaitre Vascular during the third quarter worth about $60,000. West Oak Capital LLC bought a new stake in LeMaitre Vascular in the second quarter valued at about $58,000. GAMMA Investing LLC lifted its holdings in LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock worth $68,000 after buying an additional 188 shares during the last quarter. Finally, nVerses Capital LLC grew its position in shares of LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock worth $66,000 after acquiring an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now directly owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.79% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Barrington Research upped their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. JMP Securities boosted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 20th. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday. Cantor Fitzgerald started coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 target price for the company. Finally, Oppenheimer reiterated an "outperform" rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $94.57.

LeMaitre Vascular Stock Up 0.4 %

LMAT stock traded up $0.41 during trading on Friday, reaching $100.69. 183,716 shares of the company's stock were exchanged, compared to its average volume of 124,557. LeMaitre Vascular, Inc. has a 1-year low of $52.88 and a 1-year high of $109.58. The firm has a market cap of $2.26 billion, a PE ratio of 55.02, a P/E/G ratio of 2.47 and a beta of 0.93. The company's fifty day moving average price is $97.65 and its 200-day moving average price is $89.54.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company's quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 earnings per share. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were given a $0.16 dividend. The ex-dividend date was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.64%. LeMaitre Vascular's dividend payout ratio (DPR) is 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.